Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system

por Cross, Raymond K., Chiorean, Michael, Vekeman, Francis, Xiao, Yongling, Wu, Eric, Chao, Jingdong, Wang, Anthony W.
Publicado 2019

Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies

por Louis, Edouard J., Reinisch, Walter, Schwartz, David A., Löfberg, Robert, Robinson, Anne M., Berg, Sofie, Wang, Anthony W., Maa, Jen-fue, Huang, Bidan, Pappalardo, Brandee
Publicado 2018